Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
Volume 4.26M
Average 2.07M
QGEN Total Liabilities
Everything the company owes to creditors and other parties.
Qiagen N.V.NYSE: QGEN
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 9.2% from a year ago
Total liabilities stood at $2.53B at the end of Q2 FY2026, up 9.2% from a year earlier and up 3.3% from the prior quarter. Over 3 fiscal years it compounded at -3.7% a year.
Context
- Total liabilities amounted to 43.0% of total assets at the end of Q2 FY2026, up 3.2 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +9.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.52B USD
- Year-over-year change
- +18.6%
- 4-year CAGR
- -4.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.52B | +18.6% |
| FY2024 | 2024-12-31 | 2.12B | -8.0% |
| FY2023 | 2023-12-31 | 2.31B | -18.2% |
| FY2022 | 2022-12-31 | 2.82B | -7.5% |
| FY2021 | 2021-12-31 | 3.05B | — |
Total Liabilities vs competitors
How QGEN compares with its peers on the latest reported figures
- QGEN's Jun 2026 total liabilities of $2.53B is the 7th highest of the 11 companies compared; the peer median is $3.36B.
- Its year-over-year change of +9.2% is the 4th highest of 11, against a peer median of -0.2%.
- Total liabilities amounts to 43.0% of total assets for QGEN, versus a peer median of 40.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $59.47B | +14.7% | +2.3% | 52.1% | |
| Sep 2026 | $39.66B | +37.6% | -3.4% | 42.5% | |
| Jul 2026 | $6.6B | +12.8% | +4.6% | 47.3% | |
| Jul 2026 | $4.82B | +0.2% | -10.0% | 40.0% | |
| Jun 2026 | $3.63B | -18.8% | +14.6% | 60.0% | |
| Jun 2026 | $3.08B | -0.2% | -7.0% | 30.0% | |
| Jun 2026 | $2.53B | +9.2% | -3.7% | 43.0% | |
| Jun 2026 | $838.15M | -0.2% | +10.8% | 28.4% | |
| Sep 2026 | $471.13M | -15.9% | -5.3% | 17.9% | |
| Jun 2026 | $248.16M | -42.2% | -33.9% | 41.1% | |
| Sep 2026 | $225.09M | -7.1% | +3.2% | 21.2% | |
| Peer median (excluding QGEN) | $3.36B | -0.2% | -0.5% | 40.5% | |
Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 880.52M | 730.67M | 668.08M | 663.56M | 839.01M |
| Short-term Investments | 184.79M | 687.6M | 389.7M | 489.44M | 259.91M |
| Net Receivables | 469.66M | 434.07M | 515.64M | 458.98M | 402.61M |
| Inventory | 327.53M | 357.96M | 398.39M | 279.26M | 301.89M |
| Other Current Assets | 186.48M | 132.7M | 130.9M | 26.85M | 191.66M |
| Total Current Assets | 2.11B | 2.39B | 2.15B | 1.96B | 2B |
| Property, Plant & Equipment (Net) | 638.18M | 662.17M | 765.04M | 753.61M | 923.95M |
| Goodwill | 2.35B | 2.35B | 2.48B | 2.43B | 2.7B |
| Intangible Assets | 627.44M | 544.8M | 526.82M | 303.82M | 386.43M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 72.9M | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 348.07M | 334.25M | 200.04M | 246.93M | 289.85M |
| Total Non-current Assets | 4.04B | 3.89B | 3.97B | 3.73B | 4.3B |
| Total Assets | 6.15B | 6.29B | 6.12B | 5.69B | 6.3B |
| Account Payables | 101.22M | 98.73M | 84.16M | 83.27M | 72.66M |
| Short-term Debt | 847.63M | 389.55M | 587.97M | 53.48M | 0 |
| Tax Payables | 27.67M | 13.98M | 12.48M | 24.95M | 0 |
| Deferred Revenue | 63.37M | 69M | 66.43M | 70.83M | 0 |
| Other Current Liabilities | 257.65M | 192.19M | 118.03M | 113.21M | 0 |
| Total Current Liabilities | 1.52B | 974.52M | 1.08B | 543.63M | 512.14M |
| Long-term Debt | 1.17B | 1.54B | 1B | 1.43B | 1.65B |
| Deferred Tax Liabilities | 37.59M | 17.5M | 12.8M | 22.7M | 0 |
| Deferred Revenue (Non-current) | 11.3M | 15.2M | 15.7M | 18M | 0 |
| Other Non-current Liabilities | 236.83M | 199.19M | 119.68M | 6.57M | 351.24M |
| Total Non-current Liabilities | 1.53B | 1.85B | 1.23B | 1.58B | 2.01B |
| Total Liabilities | 3.05B | 2.82B | 2.31B | 2.12B | 2.52B |
| Common Stock | 2.7M | 2.7M | 2.7M | 2.6M | 2.53M |
| Retained Earnings | 1.79B | 2.16B | 2.46B | 2.45B | 2.75B |
| Accumulated OCI | (326.67M) | (404.09M) | (433.83M) | (474.54M) | (377.31M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.1B | 3.47B | 3.81B | 3.57B | 3.78B |
| Total Debt | 2.12B | 2.03B | 1.69B | 1.61B | 1.65B |
| Net Debt | 1.24B | 1.3B | 1.02B | 945.64M | 815.42M |
Qiagen N.V.
NYSE:QGEN
Intrinsic Alpha fair value
Locked
Current Price
$49.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.